CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Drug
Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...
Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...
CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM
Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...
Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...
Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment
China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...
Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA
Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...